1. Home
  2. QD vs DSGN Comparison

QD vs DSGN Comparison

Compare QD & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QD
  • DSGN
  • Stock Information
  • Founded
  • QD 2014
  • DSGN 2017
  • Country
  • QD China
  • DSGN United States
  • Employees
  • QD N/A
  • DSGN N/A
  • Industry
  • QD Finance: Consumer Services
  • DSGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • QD Finance
  • DSGN Health Care
  • Exchange
  • QD Nasdaq
  • DSGN Nasdaq
  • Market Cap
  • QD 433.7M
  • DSGN 348.2M
  • IPO Year
  • QD 2017
  • DSGN 2021
  • Fundamental
  • Price
  • QD $2.99
  • DSGN $4.91
  • Analyst Decision
  • QD
  • DSGN Hold
  • Analyst Count
  • QD 0
  • DSGN 3
  • Target Price
  • QD N/A
  • DSGN $7.00
  • AVG Volume (30 Days)
  • QD 391.8K
  • DSGN 126.2K
  • Earning Date
  • QD 03-17-2025
  • DSGN 03-18-2025
  • Dividend Yield
  • QD N/A
  • DSGN N/A
  • EPS Growth
  • QD N/A
  • DSGN N/A
  • EPS
  • QD 0.03
  • DSGN N/A
  • Revenue
  • QD $32,502,011.00
  • DSGN N/A
  • Revenue This Year
  • QD N/A
  • DSGN N/A
  • Revenue Next Year
  • QD N/A
  • DSGN N/A
  • P/E Ratio
  • QD $111.50
  • DSGN N/A
  • Revenue Growth
  • QD 4.27
  • DSGN N/A
  • 52 Week Low
  • QD $1.52
  • DSGN $2.45
  • 52 Week High
  • QD $3.34
  • DSGN $7.77
  • Technical
  • Relative Strength Index (RSI)
  • QD 51.41
  • DSGN 53.37
  • Support Level
  • QD $2.99
  • DSGN $3.58
  • Resistance Level
  • QD $3.34
  • DSGN $5.17
  • Average True Range (ATR)
  • QD 0.16
  • DSGN 0.40
  • MACD
  • QD 0.01
  • DSGN 0.11
  • Stochastic Oscillator
  • QD 43.65
  • DSGN 83.65

About QD Qudian Inc. each representing one

Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: